Lee, Danner & Bass’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-20,000
Closed -$6K 750
2024
Q3
$6K Hold
20,000
﹤0.01% 219
2024
Q2
$9K Buy
+20,000
New +$9K ﹤0.01% 210
2023
Q4
$14K Hold
20,000
﹤0.01% 204
2023
Q3
$18K Hold
20,000
﹤0.01% 198
2023
Q2
$11K Hold
20,000
﹤0.01% 202
2023
Q1
$12K Hold
20,000
﹤0.01% 194
2022
Q4
$16K Hold
20,000
﹤0.01% 194
2022
Q3
$14K Hold
20,000
﹤0.01% 194
2022
Q2
$13K Hold
20,000
﹤0.01% 193
2022
Q1
$14K Hold
20,000
﹤0.01% 203
2021
Q4
$14K Hold
20,000
﹤0.01% 198
2021
Q3
$26K Hold
20,000
﹤0.01% 197
2021
Q2
$29K Hold
20,000
﹤0.01% 203
2021
Q1
$30K Hold
20,000
﹤0.01% 191
2020
Q4
$30K Hold
20,000
﹤0.01% 184
2020
Q3
$15K Hold
20,000
﹤0.01% 177
2020
Q2
$7K Hold
20,000
﹤0.01% 178
2020
Q1
$3K Hold
20,000
﹤0.01% 170
2019
Q4
$4K Hold
20,000
﹤0.01% 175
2019
Q3
$5K Hold
20,000
﹤0.01% 176
2019
Q2
$5K Hold
20,000
﹤0.01% 176
2019
Q1
$5K Hold
20,000
﹤0.01% 171
2018
Q4
$4K Hold
20,000
﹤0.01% 171
2018
Q3
$4K Hold
20,000
﹤0.01% 176
2018
Q2
$5K Hold
20,000
﹤0.01% 170
2018
Q1
$5K Hold
20,000
﹤0.01% 174
2017
Q4
$5K Hold
20,000
﹤0.01% 173
2017
Q3
$4K Buy
+20,000
New +$4K ﹤0.01% 167

Other funds holding NWBO

Lee, Danner & Bass's NWBO Position: Q4 2024 in Review

Lee, Danner & Bass sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2024, closing a stake of 20,000 shares — an estimated $6K sold.

Lee, Danner & Bass first reported a position in NWBO in Q3 2017 and held it in 28 quarters. The position peaked at $30K in Q1 2021. 11 funds tracked by Wall St. Rank hold NWBO as of Q4 2024.

  • Lee, Danner & Bass reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2024 after selling out during the quarter.
  • Lee, Danner & Bass sold 20,000 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2024, an estimated $6K.
  • Lee, Danner & Bass first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2017 and held it in 28 quarters.
  • Lee, Danner & Bass's Northwest Biotherapeutics, Inc. Common stock position peaked at $30K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2024.

Based on Lee, Danner & Bass's 13F filing for Q4 2024, filed 11 Feb 2025.